Universal health access depends not only on the existence of biomedical innovations but also on the institutional and economic chain that connects research financing to production, regulation, procurement, distribution, and implementation. This essay examines how geopolitical and fiscal conditions can shape that conversion. A structured critical review of 70 multidisciplinary sources was used to integrate evidence on science funding, development assistance for health, global governance, intellectual property, pharmaceutical pricing, vaccine manufacturing, supply security, universal health coverage, the Brazilian Unified Health System (Sistema Único de Saúde, SUS), and the Health Economic-Industrial Complex. The synthesis organizes the science-to-access pathway into interdependent functions spanning priority setting, research and development financing, production or procurement capacity, regulation and negotiation, distribution and implementation, and effective population access. Across these functions, the evidence indicates that scientific capacity is necessary but insufficient: fiscal space, supplier concentration, bargaining power, regulatory and industrial capacity, logistics, and territorial inequalities can alter whether innovation becomes sustainably available. The SUS illustrates how legal universality and large-scale public purchasing can coexist with financing constraints, regional inequalities, and productive dependence. The article therefore proposes that supply security, total implementation cost, absorptive capacity, and distributive effects should be incorporated into the assessment of health innovation from the stage at which scientific priorities are defined. The framework is intended to support context-sensitive analysis rather than a universal policy prescription and identifies a research agenda for empirically testing links among science funding, production strategies, resilience, and equitable access.